Proteon Therapeutics, a clinical-stage company focused on first-in-class therapeutics that meaningfully improve the lives of patients with kidney and vascular diseases has filed for a $50 million offering. The company trades on NASDAQ under the symbol “PRTO.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,